NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) REGISTRY AND TISSUE REPOSITORY

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 最近的流行病学研究表明，非酒精性脂肪性肝病(NAFLD)的患病率正在上升，目前估计为23.5%。非酒精性脂肪性肝炎(NASH)是非酒精性脂肪性肝病的一种情况，属于更严重的一端。在被诊断为NASH的患者中，16-30%的患者预计会进展为纤维化和肝硬化。 尽管这种疾病很普遍，但人们对NASH的病因和发病机制知之甚少。NASH最常见于40岁以上的肥胖、糖尿病、接受过空肠搭桥手术或接受过某些药物治疗的女性。然而，这种疾病也会发生在儿童和非肥胖者身上。NASH通常通过肝脏活检确诊，其组织学特征为大泡状脂肪改变、实质炎症、纤维化和/或肝硬变，以及Mallory透明小体的存在。 问题是，对于炎症和脂肪变性中间类别的患者的分类，或者如何对疾病的阶段进行分级，临床医生、病理学家和研究人员之间没有明确的共识。因此，对于这种疾病，有必要建立一个有效的、可重复的、被广泛接受的组织病理学分类系统。 实现NAFLD与NASH的准确诊断，以及 需要了解这些条件的自然发展，以 开发适当的治疗方法。此外，更好地理解 作为NAFLD基础的机制也将有助于预防战略。 这一登记将极大地加强为这些重要研究招募患者的过程。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Recent epidemiological research indicates that the prevalence of nonalcoholic fatty liver disease (NAFLD) is increasing, with current estimates indicating 23.5%. Nonalcoholic steatohepatitis (NASH) is one of the conditions encompassed in nonalcoholic fatty liver disease, on the more severe end of the spectrum. Of those diagnosed with NASH 16-30% are expected to progress to fibrosis and cirrhosis. Despite the disease's prevalence, the etiology and pathogenesis of NASH are poorly understood. NASH is most common in women above the age of 40 who are obese, diabetic, have had jejuneal bypass surgery, or have been receiving certain medications. However, the disease also occurs in children and non-obese individuals. NASH is usually confirmed through liver biopsy, with histological features of macrovesicular fatty changes; parenchymal inflammation; fibrosis and/or cirrhosis; and the presence of Mallory hyaline bodies. The problem is that there is no clear consensus among clinicians, pathologists and researchers as to the classification of patients with intermediate categories of inflammation and steatosis or how to grade the stage of the disease. Thus, there is significant need for a validated, reproducible, and widely accepted histo-pathological classification system for this disease. Implementation of accurate diagnosis of NAFLD versus NASH, and an understanding of the natural progression of these conditions are needed to develop appropriate treatments. Additionally, a better understanding of the mechanisms underlying NAFLD will also contribute to prevention strategies. This registry will greatly enhance the process of recruiting patients for these important studies.